The correlation of IL28B genotypes with patient demographics and disease characteristics in patients with Genotype 1 chronic hepatitis C

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12611000846921

Acronym

Predict

Enrollment

1131

Registered

2011-08-10

Start date

2011-05-31

Completion date

2012-06-29

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This is a prospective, multicentre, single arm observational non-interventional investigator initiated study by members of the Australian Liver Association Clinical Trials Network. This study will examine the distribution of the known IL28B polymorphisms (rs12979860 and rs8099917 SNPs) in patients with treatment naive genotype 1 chronic hepatitis C being considered for treatment in Australian clinics. In addition to describing the IL28B distribution in the Australian cohort, we will investigate if there is any correlation between the IL28B genotype and pre-treatment factors such as the extent of liver fibrosis, viral load and HCV genotype 1 subtype.

Interventions

A single blood sample taken for IL28B testing

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

hepatitis C (HCV) genotype 1 evidence of hepatitis C infection for at least 6 months Serological evidence of HCV infection by an anti-HCV antibody test (current or historical)

Exclusion criteria

1. Infection with any HCV genotype other than genotype 1. Patients with indeterminate or mixed subtypes will be allowed. 2. Patients currently treated, or a history of having received any interferon or ribavirin based therapy or investigational anti-HCV agents at any previous time. 3. Patients co-infected with hepatitis B, or HIV

Outcome results